Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Conditions
Keywords
stage I ovarian epithelial cancer, stage II ovarian epithelial cancer, stage III ovarian epithelial cancer, stage IV ovarian epithelial cancer, fallopian tube cancer, primary peritoneal cavity cancer
Brief summary
RATIONALE: Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This randomized phase III trial is comparing different doses of carboplatin to see how well they work in treating patients with stage IC, stage II, stage III, or stage IV ovarian, fallopian tube, or primary peritoneal cancer.
Detailed description
OBJECTIVES: Primary * Compare progression-free survival of patients with stage IC-IV ovarian epithelial, fallopian tube, or primary peritoneal cancer treated with flat-dose vs intra-patient dose-escalated carboplatin as first-line chemotherapy. Secondary * Compare the toxic effects of these regimens in these patients. * Compare the quality of life of patients treated with these regimens. * Compare overall clinical response rate and CA 125 response in patients treated with these regimens. * Compare overall survival of patients treated with these regimens. OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive a flat dose of carboplatin on day 1. * Arm II: Patients receive intra-patient dose-escalated carboplatin on day 1. In both arms, treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline, before each treatment course, and then at 2 months post-chemotherapy. Patients are followed every 2 months for 2 years, every 3 months for 1 year, every 4 months for 1 year, and then every 6 months thereafter. Peer Reviewed and Funded or Endorsed by Cancer Research UK PROJECTED ACCRUAL: A total of 1,300 patients (650 per treatment arm) will be accrued for this study.
Interventions
DRUGcarboplatin
Sponsors
NHS Greater Glasgow and Clyde
Study design
Allocation
RANDOMIZED
Primary purpose
TREATMENT
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal cancer\* * Stage IC-IV disease * Peritoneal carcinomatosis\* (ovarian-type) must not be a mucin-secreting tumor * Stage IC patients must have malignant cells in ascitic fluid or peritoneal washings, tumor on the surface of the ovary, or preoperative capsule rupture NOTE: \* Histologic confirmation of a primary source in the ovary is not required. * If biospy is not available, cytology showing an adenocarcinoma is allowed provided the following criteria is met: * Patient has a pelvis (ovarian) mass AND all of the following: * Omental cake or other metastasis is larger than 2 cm in the upper abdomen and/or regional lymph node metastasis irrespective of size OR stage IV disease * Serum CA 125/CEA ratio \> 25 or barium enema (or colonoscopy) and gastroscopy (or radiological examination of the stomach) are negative for the presence of a primary tumor and normal mammography within 6 weeks prior to study randomization * Initial cytoreductive laparotomy or biopsy required within the past 8 weeks * Cytoreductive surgery may or may not have been successful during staging laparotomy * No mixed mesodermal tumors * No borderline ovarian tumors or tumors termed possibly malignant * No adenocarcinoma of unknown origin, if histologically confirmed to be a mucin-secreting tumor * Considered unsuitable for or unwilling to receive platinum-taxane combination therapy * No concurrent endometrial cancer PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-3 Life expectancy * Not specified Hematopoietic * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 Hepatic * Bilirubin normal * AST and ALT ≤ 2.5 times upper limit of normal (ULN) * Alkaline phosphatase ≤ 5 times ULN Renal * Creatinine clearance ≥ 30 mL/min * Obstructive hydronephrosis as a cause of borderline (i.e., creatinine clearance 30-45 mL/min) renal function must be treated before study entry Cardiovascular * No hypertension * No ischemic heart disease * No myocardial infarction within the past 6 months * No congestive heart failure Other * Not pregnant or nursing * Fertile patients must use effective contraception * No symptomatic peripheral neuropathy ≥ grade 2 * No uncontrolled infection * No other severe and/or uncontrolled medical condition * No other malignancy within the past 5 years except curatively treated carcinoma in situ of the cervix or basal cell skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * No prior chemotherapy * No other concurrent cytotoxic chemotherapy until progressive disease occurs Endocrine therapy * Not specified Radiotherapy * No prior radiotherapy Surgery * See Disease Characteristics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Toxicity | — |
| Quality of life | — |
| Clinical overall response rate and CA125 response | — |
| Overall survival | — |
Countries
Australia, New Zealand, United Kingdom
Outcome results
None listed